Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3537982 in KRAS G12C-Mutant Advanced Solid Tumors
NCT04956640Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2021
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of olomorasib in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), endometrial cancer (EC), ovarian cancer, sponsored by Eli Lilly and Company. Started Jul 2021; status: active, not recruiting.
02
Drugs
olomorasib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)endometrial cancer (EC)ovarian cancer
Beyond the preview
Go deeper on NCT04956640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04956640.